Last reviewed · How we verify
NCT05336604: EpiCov
STUDY OF THE COVID-19 EPIDEMIC AND SOCIO-ECONOMIC LIVING CONDITIONS IN FRANCE
trial in General Population in 134,391 participants. Completed in 4 May 2023.
9 August 2021
Quick facts
| Lead sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 134,391 |
| Start date | 2 May 2020 |
| Primary completion | 9 August 2021 |
| Estimated completion | 4 May 2023 |
| Sites | 1 location across France |
Conditions studied
- General Population — all drugs for General Population →
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France — full company profile →
Who can join
15 and older, any sex, with General Population. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
EpiCov is a population-based cohort which aims to provide national and regional estimates of seroprevalence of SARS-CoV-2 infection and analyse relations between living conditions and the dynamics of the epidemic in France. The study population is a random sample of individuals aged 15 years and older, excluding people living in residences for the elderly and living in jail. The participants are recruited from the French national tax register and is representative of the population living in France. Home self-samples on Dried Blood Spots (DBS) for IgG and neutralizing antibodies detection were offered to a random national sub-sample of 12,114 in the 1st round of the EPICOV survey (May 2020) and to all respondents in the 2nd round (November 2020), including also serological testing for all members (≥ 6 years old) of household for 20% of index participants. A third round was perfomed in June-July 2021, without serological measurements. Overall, 134,391 participants have been enrolled in first-round (May 2020). Among them, 107 759 participated to the second round (November 2020) and 85 074 in third round (June 2021). The next wave is expected in March-april 2022.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05336604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for General Population
Currently open trials in the same condition.
- NCT06166810 — Capture of Healthy Gut Bacteria Associated to High Fiber Diet · recruiting
- NCT05758961 — Le French Gut: Characterization of Gut Microbiota Profiles in France · recruiting
- NCT05328856 — Effects of Vital Shower on Quality of Life, Immune Function, Cardiovascular Regulation and Well-being · NA · recruiting
Other Institut National de la Santé Et de la Recherche Médicale, France trials
Trials by the same sponsor.
- NCT07311213 — GENES AND AUTISM - IPSC · NA · not yet recruiting
- NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
- NCT06906042 — Multimodal Cardiovascular and Hepatic Population Imaging · recruiting
- NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
- NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05336604 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut National de la Santé Et de la Recherche Médicale, France
- Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05336604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing